Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Kawut (New York, Ny, United States of America). Determinants of survival in scleroderma-related PAH. Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension

Member's Comments

No comment yet.

Related content which might interest you: Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Improving survival in pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 218-220 Year: 2005 Impact of ILD severity and subtype on outcomes in CTD-associated PAH Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Predictors of survival of patients with chronic obstructive pulmonary disease in long-term oxygen therapy Source: Eur Respir J 2006; 28: Suppl. 50, 519s Year: 2006 Survival implications of pulmonary hypertension in end-stage COPD Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Improved survival in medically-treated chronic thromboembolic pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Emerging therapies in PAH and scleroderma-related PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Survival in pulmonary arterial hypertension (PAH): impact of 3 different periods of management Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension Source: Eur Respir J, 50 (4) 1700465; 10.1183/13993003.00465-2017 Year: 2017 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Impact of two 5-year anticoagulant strategies on survival and echocardiographic parameters in the patients with chronic thromboembolic pulmonary hypertension (CTEPH) who did not undergo pulmonary endarterectomy Source: Annual Congress 2004 - Pulmonary embolism Year: 2004 Response to increased load in systemic sclerosis-associated PAH and idiopathic PAH Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Prognostic factors affecting survival of idiopathic pulmonary fibrosis in Korean population Source: Eur Respir J 2007; 30: Suppl. 51, 578s Year: 2007 Socioeconomic status and survival in patients with pulmonary hypertension Source: ERJ Open Res, 6 (4) 00638-2020; 10.1183/23120541.00638-2020 Year: 2020 Predictors of survival in idiopathic interstitial pneumonia Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Predictors of poor outcome in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012 Survival in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 Chronic obstructive pulmonary disease and interstitial lung disease could predict poor long-term survivals after pulmonary resection for lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 38s Year: 2002